Latest Capital Raise News

Ausmon Resources Limited has announced a Share Purchase Plan offering up to 300 million shares at a discounted price to raise $540,000, aiming to reduce borrowings and fund exploration activities.

Maximus Resources Limited has issued a Target's Statement recommending shareholders accept Astral Resources NL's off-market takeover bid, which offers a significant premium and improved liquidity. The offer, valuing Maximus shares at approximately $0.073 each, aims to consolidate gold assets in Western Australia under Astral's larger portfolio.

Icetana Limited has successfully closed its renounceable pro rata entitlement offer, raising $629,422 through new share issuance, with convertible notes poised to convert into shares shortly.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Eagle Mountain Mining has completed a significant capital raise through the issue of over 518 million new shares and 129 million options, including a $3 million loan conversion, bolstering its exploration projects in Arizona.

QMines Limited has raised $6 million through a strongly supported placement, positioning the company to accelerate exploration and development at its Mt Chalmers and Develin Creek copper and gold projects.

Althea Group Holdings has raised $4 million through a share and loan note placement to boost its THC beverage production and infrastructure across North America, targeting rapid growth in the U.S. and Canada.

The Star Entertainment Group has received a $650 million debt refinancing proposal from Oaktree Capital Management, offering a potential boost to its liquidity but shadowed by significant conditions and uncertainty.

Winsome Resources has raised approximately A$7.8 million through a placement to advance its flagship Adina Lithium Project and extend the Renard Option to August 2025, with plans for an additional share purchase plan targeting A$2.5 million.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.

Mont Royal Resources has voluntarily suspended its shares on the ASX pending a critical announcement about a proposed re-compliance transaction, signaling a pivotal moment for the mining company.